Loading
The PROMID trial was the first to show that a somatostatin analogue, octreotide, slows tumour growth in midgut neuroendocrine tumours, more than doubling the time to progression compared with placebo.
Phase 3 placebo-controlled trial of 85 treatment-naive patients with well-differentiated metastatic midgut neuroendocrine tumours randomised to octreotide LAR 30 mg monthly or placebo.
Median time to tumour progression was 14.3 versus 6.0 months (hazard ratio 0.34), with the greatest benefit in patients with low hepatic tumour load and resected primary tumours.
Octreotide LAR became a standard first-line antiproliferative therapy for small intestinal neuroendocrine tumours, later joined by lanreotide after CLARINET.